We are investigating the fairness of the proposed merger of Core Scientific, Inc. (Nasdaq: CORZ) (“Core Scientific”) with CoreWeave, Inc. (“CoreWeave”) in an all-stock transaction under which Core Scientific stockholders will receive 0.1235 newly issued shares of CoreWeave Class A common stock for each share of Core Scientific common stock that they own based on a fixed exchange ratio.
Since the proposed merger was announced, Core Scientific’s stock price has fallen over 25% from a close of $18.00 per share on July 3, 2025 (the last trading day before the merger was announced) to a close of $13.48 per share on July 22, 2025.
If you remain a Core Scientific shareholder and have concerns about the fairness of the proposed merger, you may contact our firm to discuss your legal rights at no charge by completing and submitting the form below.
Why is there an investigation?
On July 7, 2025, Core Scientific announced that it had agreed to merge with CoreWeave in an all-stock transaction under which Core Scientific stockholders will receive 0.1235 newly issued shares of CoreWeave Class A common stock for each share of Core Scientific common stock that they own based on a fixed exchange ratio.
Since the proposed merger was announced, Core Scientific’s stock price has fallen over 25% from a close of $18.00 per share on July 3, 2025 (the last trading day before the merger was announced) to a close of $13.48 per share on July 22, 2025.
“Given the sharp decline in Core Scientific’s stock price since the proposed merger was announced, we are investigating whether the Core Scientific Board of Directors acted in the best interests of Core Scientific shareholders in approving the merger,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the exchange ratio agreed upon is fair to Core Scientific shareholders, and whether all material information regarding the transaction has been fully disclosed.”